Histide AG develops Recoding Therapeutics™, an extracellular, non‑mutagenic platform of Recoding Molecules™ and engineered microenvironments that direct precise cell commitment across differentiation stages. The technology aims to steer cells without introducing foreign genetic material, positioning it as an alternative to gene or RNA‑based therapies with potentially improved safety. Histide has built a broad intellectual property portfolio covering Recoding Molecules™, micro‑environmental design, and therapeutic development, and maintains international academic collaborations. The company was founded in 2014 and is based in Schindellegi/Europe. Histide is advancing an IP licensing pipeline and clinical development programs. It recently closed a Series A financing of CHF 4.5M (USD 4.6M) to support disease targeting and in vivo screening of its Recoding Molecules and microenvironments.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2014